GlassScriptPhysician profile
Sheue H Lee
NPI 1326153586
$5,863.87
in general payments reported to CMS, 2019-2025
32 companies · $471 in 2025
The $471 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $211 · 2021: $1,617 · 2022: $1,337 · 2023: $821 · 2024: $1,112 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,315 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,314.79 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,159.39 | 2020-2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $840.85 | 2019-2023 | Imfinzi |
| Novartis Pharmaceuticals Corporation | $589.80 | 2021-2025 | |
| Seagen INC. | $523.59 | 2020-2023 | Tukysa |
| Incyte Corporation | $481.74 | 2019-2023 | Monjuvi |
| E.R. Squibb & Sons, L.L.C. | $455.42 | 2021-2025 | Opdivo, Reblozyl |
| Janssen Biotech, INC. | $426.83 | 2023-2025 | Tecvayli, Darzalex, Carvykti |
| Pharmaessentia USA Corporation | $205.16 | 2024 | Besremi |
| Lilly USA, LLC | $182.46 | 2020-2024 | Verzenio, Jaypirca |
| Pfizer INC. | $156.93 | 2024 | |
| Amgen INC. | $154.37 | 2019-2021 | |
| Gilead Sciences, INC. | $89.00 | 2023 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $86.95 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $62.14 | 2021-2025 | Libtayo |
| Morphosys, US INC. | $48.08 | 2022-2023 | Monjuvi |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $38.32 | 2025 | |
| Mirati Therapeutics, INC. | $37.50 | 2023 | Krazati |
| Rigel Pharmaceuticals, INC. | $36.54 | 2021-2022 | |
| Celgene Corporation | $33.10 | 2023-2024 | Reblozyl, Pomalyst |
| Adaptive Biotechnologies Corporation | $27.71 | 2024 | Clonoseq |
| Acrotech Biopharma INC. | $26.00 | 2025 | Beleodaq |
| Myriad Genetic Laboratories, INC. | $22.89 | 2024 | Precisetumor |
| Astellas Pharma US INC | $22.30 | 2023 | Padcev |
| Helsinn Therapeutics (U.S.), INC. | $21.86 | 2024 | Valchlor |
| Takeda Pharmaceuticals U.S.A., INC. | $21.25 | 2022 | |
| Secura Bio, INC. | $20.87 | 2022 | |
| Tempus Ai, INC | $19.99 | 2024 | |
| Agios Pharmaceuticals, INC. | $17.25 | 2025 | Pyrukynd |
| Merck Sharp & Dohme LLC | $14.76 | 2019 | |
| Telix Pharmaceuticals | $14.04 | 2024 | Illuccix |
| Eisai INC. | $13.45 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheue Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.